Biology of Reproduction and Stem Cell Group, CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; Department of Life Sciences, University of Coimbra, Coimbra, Portugal.
Andrology. 2013 Nov;1(6):830-7. doi: 10.1111/j.2047-2927.2013.00127.x. Epub 2013 Sep 30.
Sperm chromatin/DNA damage can be measured by a variety of assays. However, it has been reported that these tests may lose prognostic value in Assisted Reproductive Technology (ART) cycles when assessed in post-prepared samples, possibly due to the normalizing effect promoted by sperm preparation procedures. We have recently implemented a modified version of the Diff-Quik staining assay that allows for the evaluation of human sperm chromatin status in native samples, together with standard sperm morphology assessment. However, the value of this parameter in terms of predicting in vitro fertilization (IVF) and Intracytoplasmic sperm injection (ICSI) outcomes after sperm selection is unknown. In this study, data from 138 couples undergoing in vitro fertilization (IVF) or Intracytoplasmic sperm injection (ICSI) treatments showed that sperm chromatin integrity was significantly improved after density gradient centrifugation and swim up (p < 0.001), but no correlations were found with fertilization or embryo development rates (p > 0.05). However, sperm samples presenting lower percentages of damaged chromatin were associated with better quality (Grade I) embryos in both ART procedures (p < 0.05) and clinical pregnancy among IVF couples (p < 0.05). Furthermore, regression analysis confirmed the clinical value of Diff-Quik staining in predicting IVF (but not ICSI) clinical pregnancy (OR: 0.927, 95% CI: 0.871-0.985, p = 0.015), and a threshold value of 34.25% for this parameter was established. The proportion of IVF couples achieving a clinical pregnancy was reduced 1.9-fold when the percentage of abnormal dark staining was ≥34.25% (p = 0.05). In conclusion, the Diff-Quik staining assay provides useful information regarding ART success, particularly in IVF cycles, where some degree of 'natural' sperm selection may occur; but not in ICSI, where sperm selection is operator dependent. This quick and low-cost assay is suggested as an alternative method to detect sperm chromatin status in minimal clinical settings, when no other well-established and robust assays (e.g. Sperm chromatin structure assay, terminal deoxynucleotidyl transferase-mediated dUDP nick-end labelling) are available.
精子染色质/DNA 损伤可以通过多种检测方法来测量。然而,据报道,在辅助生殖技术(ART)周期中,这些检测在经过预处理的样本中可能会失去预测价值,这可能是由于精子准备过程中的正常化作用。我们最近实施了一种改良的 Diff-Quik 染色检测方法,允许在原生样本中评估人类精子染色质状态,同时评估标准精子形态。然而,在精子选择后,关于预测体外受精(IVF)和胞浆内单精子注射(ICSI)结果的这个参数的价值尚不清楚。在这项研究中,来自 138 对接受体外受精(IVF)或胞浆内单精子注射(ICSI)治疗的夫妇的数据显示,密度梯度离心和游泳后精子染色质完整性显著提高(p<0.001),但与受精或胚胎发育率无相关性(p>0.05)。然而,在两种 ART 程序中(p<0.05)和 IVF 夫妇的临床妊娠中(p<0.05),染色质损伤百分比较低的精子样本与更好质量(I 级)胚胎相关。此外,回归分析证实了 Diff-Quik 染色在预测 IVF(但不是 ICSI)临床妊娠中的临床价值(OR:0.927,95%CI:0.871-0.985,p=0.015),并为该参数建立了 34.25%的阈值。当异常暗染色的百分比≥34.25%时,IVF 夫妇实现临床妊娠的比例降低了 1.9 倍(p=0.05)。总之,Diff-Quik 染色检测为 ART 成功提供了有用的信息,特别是在 IVF 周期中,可能会发生某种程度的“自然”精子选择;而在 ICSI 中则不然,因为精子选择依赖于操作者。在没有其他成熟和稳健的检测方法(例如精子染色质结构检测、末端脱氧核苷酸转移酶介导的 dUDP 末端标记)可用的情况下,建议将这种快速且低成本的检测方法作为检测最小临床环境中精子染色质状态的替代方法。